Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET

May 1, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

April 23, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

April 17, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

March 12, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Host Upcoming Conference Calls

March 3, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

February 18, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

January 15, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

January 8, 2026 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; that the … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Host Upcoming Conference Calls

November 7, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
Scroll to Top